The Renin-Angiotensin System in Essential Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-04-30

Study Completion Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RAS Quantification in Patients With Aliskiren or Candesartan

NCT01827202

Hypertension Chronic Kidney Disease Proteinuria

COMPLETED PHASE4

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

NCT01252238

Insulin Sensitivity Aortic Compliance Diastolic Function

TERMINATED NA

A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

NCT00171353

Hypertension

COMPLETED PHASE4

Clinical One-stage Controlled Study of reSistant Arterial Hypertension for the desiGning of a personAlized Approach to Therapy

NCT05899920

Resistant Arterial Hypertension

RECRUITING NA

Nighttime Valsartan in Hemodialysis Hypertension

NCT03594825

Hypertension;Nephropathy

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enalapril 20 mg bd

Intervention Type DRUG

Candesartan 8 mg bd

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Essential Hypertension
* SBP 140-159 mmHg
* DBP 90-99 mmHg

Exclusion Criteria

* Intolerance of or allergy to ACE Inhibitors or ARBS
* Pregnant or Breastfeeding
* Pre-menopausal women
* Uncontrolled cardiac or renal failure
* Diabetes mellitus

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No